Phase 3 Readout
CRNX: Phase 3 Topline: Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Effi
December 31, 2026 · raphamin. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2026
- Company
- Crinetics Pharmaceuticals, Inc. (CRNX)
- Drug
- raphamin
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of the Effi
- Drug
- raphamin
- Indication
- Cystitis Chronic; Cystitis Bacterial; Recurrence of Chronic Bacterial Cystitis
Other upcoming events for CRNX
Phase 3 ReadoutPhase 3 Topline: Diagnostic Testing of Post-Traumatic Stress Disorder (PTSD) Using the Senseye Diagnostic Tool in Adu
Phase 3 ReadoutPhase 3 Topline: Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Plac
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled Trial of Dalargin for the Prevention of Postoperative